Drug
GS-621763 clinical trials
Also written VV116 and JT001.
- studies test it
- 16
- open now
- 0
- in phase 3
- 5
- first study started
- 2021
How studies write it
Studies that test it under each name
Studies by the year they started
16 studies that test it; most in 2022 (5)
| Year | Studies |
|---|---|
| 2021 | 4 |
| 2022 | 5 |
| 2023 | 5 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 10
- Phase 2
- 2
- Phase 3
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 16 · Other 0
Vigonvita Life Sciences (7) · Shanghai Vinnerna Biosciences Co., Ltd. (7) · Shanghai JunTop Biosciences Co., LTD (1) · Jeil Pharmaceutical Co., Ltd. (1)
Studies
Open first, then newest update. How each study uses GS-621763 is read from its arms, and is right about nine times in ten.
Testing it · 16
- A Study of Deuremidevir Hydrobromide for Suspension in Chinese Infants Hospitalized With RSVCompletedPhase 2Vigonvita Life SciencesNCT06206720Written as Deuremidevir Hydrobromide for Suspension
- The Mass Balance Study of [14C]JT001CompletedPhase 1Shanghai Vinnerna Biosciences Co., Ltd.NCT05802810Written as [14C]JT001
- A Study to Evaluate the Bioavailability, Food Effect and Pharmacokinetics of Deuremidevir Hydrobromide for SuspensionCompletedPhase 1Vigonvita Life SciencesNCT05932459Written as Deuremidevir Hydrobromide for Suspension 100mg
- A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Deuremidevir Hydrobromide for SuspensionCompletedPhase 1Vigonvita Life SciencesNCT06328400Written as Deuremidevir Hydrobromide for Suspension
- A Study in Subjects With Liver Function Injury and Subjects With Normal Liver FunctionCompletedPhase 1Shanghai Vinnerna Biosciences Co., Ltd.NCT06093230Written as Deuremidevir Hydrobromide Tablets
- A Study in Elderly Chinese Subjects With Underlying DiseasesCompletedPhase 1Shanghai Vinnerna Biosciences Co., Ltd.NCT06093308Written as Deuremidevir Hydrobromide Tablets
- A Study in Subjects With Renal Impairment Compared to Subjects With Normal Renal FunctionCompletedPhase 1Shanghai Vinnerna Biosciences Co., Ltd.NCT05895812Written as Deuremidevir Hydrobromide Tablets
- JT001 (VV116) for the Early Treatment of COVID-19TerminatedPhase 2/3Shanghai JunTop Biosciences Co., LTDNCT05242042Written as JT001
- JT001 (VV116) for the Treatment of COVID-19CompletedPhase 3Shanghai Vinnerna Biosciences Co., Ltd.NCT05582629Written as JT001
- Evaluate the Pharmacokinetics, Safety and Tolerability of JT001 TabletsWithdrawnPhase 1Shanghai Vinnerna Biosciences Co., Ltd.NCT05355077Written as JT001 200mg Bid
- Efficacy and Safety of JT001 (VV116) Compared With FavipiravirTerminatedPhase 3Shanghai Vinnerna Biosciences Co., Ltd.NCT05279235Written as JT001
- Efficacy and Safety of JT001 (VV116) Compared With PaxlovidCompletedPhase 3Vigonvita Life SciencesNCT05341609Written as JT001
- Safety and Pharmacokinetics Study of Single Ascending Doses of VV116 in Healthy VolunteersCompletedPhase 1Vigonvita Life SciencesNCT05227768Written as VV116 25mg Group
- To Evaluate the Efficacy and Safety of JT-001 add-on in Paatients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and DapagliflozinStatus unknownPhase 3Jeil Pharmaceutical Co., Ltd.NCT05101135Written as JT-001
- Safety and Pharmacokinetics Study of Multiple Ascending Doses of VV116 in Healthy VolunteersCompletedPhase 1Vigonvita Life SciencesNCT05201690Written as VV116 200 mg Group
- Food Effect on Pharmacokinetic Profiles of VV116 Administered Orally to Chinese Healthy VolunteersCompletedPhase 1Vigonvita Life SciencesNCT05221138Written as VV116
Codes
What other systems call GS-621763 · ClinicalTrials.gg INT001875
- MeSH (NLM) C000722705GS-621763One source NLM
- UNII (FDA) 83BU3492RPGS-621763One source NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000722705 | GS-621763 | One source NLM |
| UNII (FDA) | 83BU3492RP | GS-621763 | One source NLM |
Also registered as deuremidevir hydrobromide (UNII P4L9Q2T94L) and jt-001 (UNII 43K4X7JG75).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.